Ab­b­Vie share­hold­er joins the grow­ing ranks of crit­ics, call­ing for an in­de­pen­dent chair­man

There’s a down­side to hav­ing the world’s high­est earn­ing drug in the port­fo­lio. And Ab­b­Vie CEO and chair­man Richard Gon­za­lez would be able to tell you all about it.

Ab­b­Vie’s $20 bil­lion in rev­enue from Hu­mi­ra last year has earned high lev­el crit­i­cism from US Sen­a­tors of both par­ties for a com­pen­sa­tion pack­age tied to ris­ing Hu­mi­ra rev­enue, a long run­ning court bat­tle over the “patent thick­et” it’s used to ex­tend its de­fense against gener­ics un­til pos­si­bly 2023 and now a share­hold­er flank at­tack on cor­po­rate gov­er­nance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER